Back to Directory
Last Updated: 05/05/2026
Artios Pharma
Cambridge
Founded 2016
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells.
The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA polymerase theta inhibitor.
Artios also has pre-clinical DDR-ADC programmes combining its DDR expertise with antibody-drug conjugate technology.
Company Notes
Member of